Glutamic acid 709 substitutions highlight the importance of the interaction between androgen receptor helices H3 and H12 for androgen and antiandrogen actions

Molecular Endocrinology

Volumn 20, Issue 4, 2006, Pages 724-734

  Georget, Virginie ^a,e   Bourguet, William ^b   Lumbroso, Serge ^a,c,f   Makni, Salouah ^d   Sultan, Charles ^a,c   Nicolas, Jean Claude ^a  

^a INSERM   (France)

^b CNRS   (France)

^c LAPEYRONIE HOSPITAL   (France)

^d CHILDREN S HOSPITAL   (Tunisia)

^e SORBONNE UNIVERSITÉ   (France)

^f DEPARTMENT OF NEUROLOGY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE ACETATE; GLUTAMIC ACID; HYDROXYFLUTAMIDE; NILUTAMIDE; PARTIAL AGONIST; TYROSINE;

AGONIST; AMINO ACID SUBSTITUTION; ANDROGEN INSENSITIVITY SYNDROME; ARTICLE; CASE REPORT; COMPARATIVE STUDY; DRUG ACTIVITY; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HORMONE SENSITIVITY; HORMONE STRUCTURE; HUMAN; MOLECULAR INTERACTION; MUTATION; NEWBORN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

AMINO ACID SUBSTITUTION; ANDROGEN ANTAGONISTS; ANDROGEN-INSENSITIVITY SYNDROME; ANDROGENS; ANIMALS; BASE SEQUENCE; CELL LINE; CYPROTERONE ACETATE; DNA, COMPLEMENTARY; HUMANS; INFANT; MALE; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, ANDROGEN; RECOMBINANT PROTEINS;

EID: 33645395548     PISSN: 08888809     EISSN: 08888809     Source Type: Journal    
DOI: 10.1210/me.2005-0419     Document Type: Article

References (38)

1. Quigley CA, Debellis A, Marschke KB, Elawady MK, Wilson EM, French FS 1995 Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 16:271-321
2. Mangelsdorf D, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily: the second decade. Cell 83:835-839
3. Bourguet W, Germain P, Gronemeyer H 2000 Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 21:381-388
4. Moras D, Gronemeyer H 1998 The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol 10:384-391
5. Dubbink HJ, Hersmus R, Verma CS, van der Korput HA, Berrevoets CA, van Tol J, Ziel-van der Made AC, Brinkmann AO, Pike AC, Trapman J 2004 Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor. Mol Endocrinol 18:2132-2150
6. Sultan C, Lumbroso S, Paris F, Jeandel C, Terouanne B, Belon C, Audran F, Poujol N, Georget V, Gobinet J, Jalaguier S, Auzou G, Nicolas JC 2002 Disorders of androgen action. Semin Reprod Med 20:217-228
7. Lumbroso S, Wagschal A, Bourguet W, Georget V, Mazen I, Servant N, Audran F, Sultan C, Auzou G 2004 A new mutation of the androgen receptor, P817A, causing partial androgen insensitivity syndrome: in vitro and structural analysis. J Mol Endocrinol 32:679-687
8. Alen P, Claessens F, Verhoeven G, Rombauts W, Peeters B 1999 The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol 19:6085-6097
9. Veldscholte J, Berrevoets CA, Mulder E 1994 Studies on the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol 49:341-346
10. Warriar N, Page N, Koutsilieris M, Govindan MV 1994 Antiandrogens inhibit human androgen receptor-dependent gene transcription activation in the human prostate cancer cells LNCaP. Prostate 24:176-186
11. Poujol N, Wurtz JM, Tahiri B, Lumbroso S, Nicolas JC, Moras D, Sultan C 2000 Specific recognition of androgens by their nuclear receptor. A structure-function study. J Biol Chem 275:24022-24031
12. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M 2003 Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 63:149-153
13. Yeh S, Miyamoto H, Shima H, Chang C 1998 From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc Natl Acad Sci USA 95:5527-5532
14. Wang C, Young WJ, Chang C 2000 Isolation and characterization of the androgen receptor mutants with divergent transcriptional activity in response to hydroxyflutamide. Endocrine 12:69-76
15. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS 1995 Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 16:271-321
16. Kuil CW, Berrevoets CA, Mulder E 1995 Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. J Biol Chem 270:27569-27576
17. Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, Basler S, Schafer M, Egner U, Carrondo MA 2000 Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 275:26164-26171
18. Sack JS, Kish KF, Wang C, Attar RM, Kiefer SE, An Y, Wu GY, Scheffler JE, Salvati ME, Krystek Jr SR, Weinmann R, Einspahr HM 2001 Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci USA 98:4904-4909
19. Anghel SI, Perly V, Melancon G, Barsalou A, Chagnon S, Rosenauer A, Miller WH, Mader S 2000 Aspartate 351 of estrogen receptor α is not crucial for the antagonist activity of antiestrogens. J Biol Chem 275:20867-20872
20. Levenson AS, Jordan VC 1998 The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res 58:1872-1875
21. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL 1998 The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937
22. Wolf DM, Jordan VC 1994 The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat 31:129-138
23. Webb P, Nguyen P, Valentine C, Weatherman RV, Scanlan TS, Kushner PJ 2000 An antiestrogen-responsive estrogen receptor-α mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen. J Biol Chem 275:37552-37558
24. Yamamoto Y, Wada O, Suzawa M, Yogiashi Y, Yano T, Kato S, Yanagisawa J 2001 The tamoxifen-responsive estrogen receptor α mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes. J Biol Chem 276:42684-42691
25. Chen JD, Evans RM 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377:454-457
26. Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H 1996 TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15:3667-3675
27. Karvonen U, Janne OA, Palvimo JJ 2002 Pure antiandrogens disrupt the recruitment of coactivator GRIP1 to colocalize with androgen receptor in nuclei. FEBS Lett 523:43-47
28. Black BE, Vitto MJ, Gioeli D, Spencer A, Afshar N, Conaway MR, Weber MJ, Paschal BM 2004 Transient, ligand-dependent arrest of the androgen receptor in subnuclear foci alters phosphorylation and coactivator interactions. Mol Endocrinol 18:834-850
29. Kallenberger BC, Love JD, Chatterjee VK, Schwabe JW 2003 A dynamic mechanism of nuclear receptor activation and its perturbation in a human disease. Nat Struct Biol 10:136-140
30. Kang HY, Yeh S, Fujimoto N, Chang C 1999 Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem 274:8570-8576
31. Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, Greene GL 2002 Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 9:359-364
32. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT 2005 Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 102:6201-6206
33. Hara T, Kouno J, Nakamura K, Kusaka M, Yamaoka M 2005 Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells. Prostate 65:268-275
34. Lumbroso S, Lobaccaro JM, Georget V, Leger J, Poujol N, Terouanne B, Evain-Brion D, Czernichow P, Sultan C 1996 A novel substitution (Leu707Arg) in exon 4 of the androgen receptor gene causes complete androgen resistance. J Clin Endocrinol Metab 81:1984-1988
35. Georget V, Terouanne B, Nicolas JC, Sultan C 2002 Mechanism of antiandrogen action: key role of hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry 41:11824-11831
36. van Laar JH, Voorhost-Ogink MM, Zegers ND, Boersma WJA, Claassen E, van der Korput JAGM, Ruizeveld de Winter JA, Van der Kwast TH, Mulder E, Trapman J, Brinkmann AO 1989 Characterization of polyclonal antibodies against the N-terminal domain of the human androgen receptor. Mol Cell Endocr 67:29-38
37. Jones TA, Zou JY, Cowan SW, Kjeldgaard 1991 Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47(Pt 2):110-119
38. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang JS, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL 1998 Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54(Pt 5):905-921